- Home
- DCI vs HALO Comparison
DCI vs HALO Comparison
Compare DCI & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- HALO
- Stock Information
- Founded
- DCI 1915
- HALO 1998
- Country
- DCI United States
- HALO United States
- Employees
- DCI N/A
- HALO N/A
- Industry
- DCI Pollution Control Equipment
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DCI Industrials
- HALO Health Care
- Exchange
- DCI Nasdaq
- HALO Nasdaq
- Market Cap
- DCI 8.2B
- HALO 7.3B
- IPO Year
- DCI 1987
- HALO N/A
- Fundamental
- Price
- DCI $68.80
- HALO $57.75
- Analyst Decision
- DCI Hold
- HALO Buy
- Analyst Count
- DCI 4
- HALO 9
- Target Price
- DCI $74.00
- HALO $62.78
- AVG Volume (30 Days)
- DCI 471.9K
- HALO 1.1M
- Earning Date
- DCI 02-27-2025
- HALO 02-18-2025
- Dividend Yield
- DCI 1.56%
- HALO N/A
- EPS Growth
- DCI 16.62
- HALO 63.33
- EPS
- DCI 3.44
- HALO 3.43
- Revenue
- DCI $3,640,100,000.00
- HALO $1,015,324,000.00
- Revenue This Year
- DCI $5.29
- HALO $23.48
- Revenue Next Year
- DCI $5.19
- HALO $18.16
- P/E Ratio
- DCI $20.06
- HALO $16.84
- Revenue Growth
- DCI 6.13
- HALO 22.44
- 52 Week Low
- DCI $66.01
- HALO $37.73
- 52 Week High
- DCI $78.95
- HALO $65.53
- Technical
- Relative Strength Index (RSI)
- DCI 42.52
- HALO 62.93
- Support Level
- DCI $68.33
- HALO $56.07
- Resistance Level
- DCI $69.82
- HALO $60.67
- Average True Range (ATR)
- DCI 1.07
- HALO 1.43
- MACD
- DCI -0.16
- HALO -0.22
- Stochastic Oscillator
- DCI 17.09
- HALO 48.86
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.